Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …

Background Low-dose erlotinib may be as effective as gefitinib or erlotinib at full dose in non-
small cell lung cancer (NSCLC) patients with activating mutations of the epidermal growth …

Backgrounds Efficacy of gefitinib therapy strongly depends on epidermal growth factor
receptor (EGFR)-mutation status in Asian patients with non-small cell lung cancer. Recently …

Background: A phase III trial was conducted to compare the safety and efficacy of erlotinib
with that of gefitinib in advanced non-small cell lung cancer harbouring epidermal growth …

Introduction Exon 19 deletions and the exon 21 L858R mutation of the epidermal growth
factor receptor gene (EGFR) predict activity of EGFR tyrosine kinase inhibitors, including …

7522 Background: When EGFR compound mutants (exon 19 deletions or L858R
plusT790M) are present at the time of clinical resistance to erlotinib, patients attain longer …

BACKGROUND Erlotinib is a standard first‐line therapy for patients who have metastatic
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are an effective
treatment for advanced non-small cell lung cancer. The objective of the present study was to …

PURPOSE: The use of erlotinib after gefitinib failure in patients with non-small cell lung
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …

7503 Background: EGFR tyrosine kinase activating mutations are present in 10-26% of
NSCLC tumors and are associated with increased response to gefitinib and erlotinib …